| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Kwinten Sliepen | Q90182952 |
| Iván Del Moral-Sánchez | Q91609975 | ||
| P2860 | cites work | HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 |
| Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination | Q24646818 | ||
| Self-assembling protein nanoparticles in the design of vaccines | Q26767097 | ||
| Immune correlates of vaccine protection against HIV-1 acquisition | Q26778573 | ||
| Antibody promiscuity: Understanding the paradigm shift in antigen recognition | Q26801316 | ||
| Structural insights on the role of antibodies in HIV-1 vaccine and therapy | Q26829461 | ||
| Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination | Q27008256 | ||
| DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques | Q27316075 | ||
| Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site | Q27319450 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Molecular architecture of native HIV-1 gp120 trimers | Q27651385 | ||
| Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 | ||
| Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen | Q42221772 | ||
| First steps toward a globally effective HIV/AIDS vaccine. | Q42255094 | ||
| A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity | Q42265160 | ||
| Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model | Q42377340 | ||
| Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1. | Q42795407 | ||
| Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies | Q43611862 | ||
| Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes | Q43612537 | ||
| Heterologous protection against influenza by injection of DNA encoding a viral protein | Q43828996 | ||
| Genetic immunization is a simple method for eliciting an immune response | Q43857336 | ||
| Direct gene transfer into mouse muscle in vivo | Q44656494 | ||
| Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. | Q44809362 | ||
| Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials | Q45323629 | ||
| Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation | Q45413707 | ||
| Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. | Q45417687 | ||
| Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data | Q45745461 | ||
| Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev | Q45771982 | ||
| Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys | Q45860095 | ||
| HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage | Q46454115 | ||
| Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. | Q46631754 | ||
| The expanding epidemic of HIV-1 in the Russian Federation. | Q47095099 | ||
| Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations | Q47118310 | ||
| Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models | Q47215738 | ||
| Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens | Q47232975 | ||
| Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. | Q47257240 | ||
| Immunogenicity in rabbits of SOSIP trimers from clades A, B and C, given individually, sequentially or in combinations | Q47549195 | ||
| Targeted Elimination of Immunodominant B Cells Drives the Germinal Center Reaction toward Subdominant Epitopes | Q47560170 | ||
| Neutralization tiers of HIV-1. | Q47562235 | ||
| Antibodies expose multiple weaknesses in the glycan shield of HIV. | Q47681955 | ||
| mRNA vaccines - a new era in vaccinology | Q47736893 | ||
| A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer | Q64263374 | ||
| Protein and Glycan Mimicry in HIV Vaccine Design. | Q64983102 | ||
| Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. | Q64984736 | ||
| Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells | Q73948770 | ||
| Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 | Q88985874 | ||
| Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers | Q90680433 | ||
| Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies | Q90745914 | ||
| Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses | Q91451199 | ||
| Broadly Neutralizing Antibodies against HIV: Back to Blood | Q91812746 | ||
| Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance | Q91958986 | ||
| Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies | Q92290331 | ||
| Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence | Q92382176 | ||
| Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques | Q92382854 | ||
| HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells | Q93040513 | ||
| Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms | Q93150667 | ||
| Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? | Q35961192 | ||
| Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity | Q36086357 | ||
| Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity | Q36094699 | ||
| Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike | Q36100426 | ||
| Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens | Q36102994 | ||
| Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. | Q36132706 | ||
| HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. | Q36132728 | ||
| A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. | Q36149102 | ||
| Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice | Q36159067 | ||
| Nonviral delivery of self-amplifying RNA vaccines | Q36221799 | ||
| Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies | Q36262823 | ||
| Gene inoculation generates immune responses against human immunodeficiency virus type 1 | Q36284135 | ||
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 | ||
| Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) | Q36376210 | ||
| New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency | Q36433894 | ||
| An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses | Q36446900 | ||
| Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes | Q36624369 | ||
| Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. | Q36627503 | ||
| Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens | Q36638450 | ||
| DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China. | Q36694841 | ||
| Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies | Q36750045 | ||
| Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1 | Q36760169 | ||
| Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection | Q36951283 | ||
| High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. | Q36957800 | ||
| Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles | Q37060947 | ||
| Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. | Q37060986 | ||
| Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination | Q37099729 | ||
| Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein | Q37123584 | ||
| Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10 | Q37171251 | ||
| Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages | Q37221575 | ||
| Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies | Q37246321 | ||
| Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. | Q37276912 | ||
| HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies | Q37293480 | ||
| Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 | Q27675468 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer | Q27680497 | ||
| Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign | Q27681806 | ||
| Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers | Q27683553 | ||
| Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies | Q27690140 | ||
| Accurate design of megadalton-scale two-component icosahedral protein complexes | Q27722473 | ||
| DNA vaccine for cancer immunotherapy | Q28080919 | ||
| Progress and prospects: immune responses to viral vectors | Q28264531 | ||
| Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes | Q28271300 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule | Q28646808 | ||
| HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers | Q28647225 | ||
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination | Q28656365 | ||
| A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity | Q28727030 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein | Q29306052 | ||
| Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope | Q29307502 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain | Q29618472 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Evolutionary and immunological implications of contemporary HIV-1 variation. | Q30329205 | ||
| An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. | Q30375785 | ||
| Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein | Q33571825 | ||
| Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
| A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure | Q33592001 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection | Q33702217 | ||
| Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein | Q33711154 | ||
| Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | Q33712291 | ||
| Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys | Q33712578 | ||
| Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. | Q33759392 | ||
| Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. | Q51926211 | ||
| The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. | Q52020458 | ||
| Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. | Q52582170 | ||
| Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1. | Q52655238 | ||
| Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. | Q52688325 | ||
| Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. | Q54209542 | ||
| HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. | Q54210145 | ||
| Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. | Q54217790 | ||
| A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. | Q54237723 | ||
| Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. | Q55265892 | ||
| Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. | Q55512707 | ||
| Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques | Q56517308 | ||
| Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen | Q57010966 | ||
| Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies | Q57091049 | ||
| IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells | Q57117718 | ||
| One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice | Q57157197 | ||
| DNA vaccines against tuberculosis | Q57203104 | ||
| The expanding array of HIV broadly neutralizing antibodies | Q57460198 | ||
| Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth | Q57796335 | ||
| Recent progress in broadly neutralizing antibodies to HIV | Q58569712 | ||
| Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes | Q58589975 | ||
| Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers | Q58721980 | ||
| Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization | Q58730221 | ||
| Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer | Q58747611 | ||
| Consensus and Ancestral State HIV Vaccines | Q59192523 | ||
| Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes | Q59349684 | ||
| Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer | Q59358743 | ||
| Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers | Q60908099 | ||
| HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design | Q60913187 | ||
| Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide | Q61795909 | ||
| Reprogramming the antigen specificity of B cells using genome-editing technologies | Q61814105 | ||
| Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery | Q63246454 | ||
| Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA | Q63246643 | ||
| Immunological basis for enhanced immunity of nanoparticle vaccines | Q63408829 | ||
| Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques | Q63740489 | ||
| Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus | Q64119844 | ||
| CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells | Q64242076 | ||
| Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells | Q37295542 | ||
| Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. | Q37316019 | ||
| Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation | Q37318042 | ||
| T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces | Q37333743 | ||
| Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens | Q37417794 | ||
| Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. | Q37446484 | ||
| Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques | Q37499531 | ||
| Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. | Q37548329 | ||
| Improvement of antibody responses by HIV envelope DNA and protein co-immunization. | Q37588371 | ||
| Native-like Env trimers as a platform for HIV-1 vaccine design | Q37633417 | ||
| Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies | Q37634061 | ||
| Immunogenicity of HIV-1 envelope glycoprotein oligomers | Q37667740 | ||
| The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. | Q37667754 | ||
| Lessons learned from HIV vaccine clinical efficacy trials | Q37724091 | ||
| An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability | Q37728775 | ||
| Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein | Q37742876 | ||
| Correlates of protection induced by vaccination | Q37750121 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Virus-like particle-based human vaccines: quality assessment based on structural and functional properties | Q38152530 | ||
| mRNA-based therapeutics--developing a new class of drugs | Q38252360 | ||
| mRNA transcript therapy | Q38264088 | ||
| Vaccine nanoparticles for protection against HIV infection | Q38405327 | ||
| Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development | Q38454489 | ||
| Developments in Viral Vector-Based Vaccines | Q38582090 | ||
| HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies | Q38665463 | ||
| Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses | Q38737582 | ||
| Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires | Q38747466 | ||
| Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines | Q38981064 | ||
| Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits | Q38989507 | ||
| Host controls of HIV broadly neutralizing antibody development | Q39108769 | ||
| Identification and specificity of broadly neutralizing antibodies against HIV | Q39108796 | ||
| Lipid Nanoparticle Systems for Enabling Gene Therapies | Q39244558 | ||
| FDA guidance on prophylactic DNA vaccines: analysis and recommendations | Q33759465 | ||
| Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect | Q33826983 | ||
| Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches | Q33830824 | ||
| Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys | Q33834916 | ||
| How advances in immunology provide insight into improving vaccine efficacy. | Q33896995 | ||
| Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara | Q33935092 | ||
| DNA vaccines: a key for inducing long-term cellular immunity | Q33970997 | ||
| Why HIV virions have low numbers of envelope spikes: implications for vaccine development | Q34016070 | ||
| Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence | Q34016706 | ||
| Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer | Q34059543 | ||
| Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination | Q34074750 | ||
| Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies | Q34094476 | ||
| Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization | Q34099837 | ||
| Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies | Q34114798 | ||
| Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
| B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study | Q34273373 | ||
| Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins | Q34332728 | ||
| Immunogen sequence: the fourth tier of AIDS vaccine design | Q34337482 | ||
| Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. | Q34361680 | ||
| Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? | Q34364357 | ||
| Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine | Q34373275 | ||
| Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody | Q34526404 | ||
| Ancestral and consensus envelope immunogens for HIV-1 subtype C. | Q34539222 | ||
| Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs | Q34539819 | ||
| Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals | Q34571277 | ||
| Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo | Q34593860 | ||
| A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects | Q34593969 | ||
| Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study | Q34673391 | ||
| Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen | Q34717906 | ||
| DNA vaccines: ready for prime time? | Q34824179 | ||
| Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies | Q34982715 | ||
| Polyreactivity and autoreactivity among HIV-1 antibodies | Q34992787 | ||
| Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions | Q35006601 | ||
| A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component | Q35076748 | ||
| Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected | Q35076987 | ||
| A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene | Q35110976 | ||
| International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations | Q35112755 | ||
| HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development | Q35172770 | ||
| Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer | Q35217426 | ||
| A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses | Q35569049 | ||
| Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. | Q35641498 | ||
| Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes | Q35745442 | ||
| Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost | Q35760486 | ||
| Technologies for enhanced efficacy of DNA vaccines | Q35802958 | ||
| Vector Design for Improved DNA Vaccine Efficacy, Safety and Production | Q35826665 | ||
| HIV DNA Vaccine: Stepwise Improvements Make a Difference | Q35826742 | ||
| Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins | Q35933555 | ||
| Co-receptors for HIV-1 entry | Q39265878 | ||
| HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes | Q39402539 | ||
| Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice | Q39407795 | ||
| A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure | Q39588870 | ||
| Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer | Q39949085 | ||
| Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models | Q40071705 | ||
| Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization | Q40073525 | ||
| HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers | Q40089181 | ||
| Potent and broad HIV-neutralizing antibodies in memory B cells and plasma | Q40092127 | ||
| Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies | Q40103798 | ||
| Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach | Q40198048 | ||
| Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop | Q40198060 | ||
| Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation | Q40226810 | ||
| HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells | Q40348395 | ||
| Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. | Q40353574 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. | Q40449526 | ||
| Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. | Q40471380 | ||
| Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies | Q40568483 | ||
| Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion | Q40613093 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| The prevalence of IgG and IgA against adenoviruses in serum of children aged 11-26 months, hospitalised in the Clinical Paediatric Hospital in Warsaw, Poland | Q40758113 | ||
| Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design | Q41042362 | ||
| The influence of virus structure on antibody responses and virus serotype formation | Q41305357 | ||
| Immunosilencing a highly immunogenic protein trimerization domain. | Q41506957 | ||
| RNA-based vaccination: sending a strong message | Q41573749 | ||
| Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. | Q41611835 | ||
| HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine | Q41918753 | ||
| Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. | Q41924763 | ||
| Immunogenicity of the outer domain of a HIV-1 clade C gp120. | Q41961460 | ||
| Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate | Q42054413 | ||
| Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies | Q42170932 | ||
| In vivo protection by broadly neutralizing HIV antibodies | Q42196644 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P304 | page(s) | 1127-1143 | |
| P577 | publication date | 2019-11-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Strategies for inducing effective neutralizing antibody responses against HIV-1 | |
| P478 | volume | 18 |
| Q89936366 | The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans | cites work | P2860 |
Search more.